Kevin Koch compensation by year
Edgewise Therapeutics Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $425,000 | $524,500 | $572,000 | $594,880 | $618,675 | $670,000 |
| Bonus | $0 | $0 | $0 | — | — | — |
| Stock awards | $0 | $0 | $249,375 | $0 | $1,225,469 | $1,171,625 |
| Option awards | $1,010,038 | $4,273,240 | $4,193,069 | $3,070,335 | $5,300,903 | $5,041,621 |
| Non-equity incentive | $255,000 | $316,250 | $328,900 | $297,440 | $442,353 | $462,300 |
| Pension and deferred compensation | $0 | $0 | $0 | — | — | — |
| All other | $0 | $4,583 | $12,200 | $13,200 | $13,800 | $14,000 |
| Total | $1,690,038 | $5,118,573 | $5,355,544 | $3,975,855 | $7,601,200 | $7,359,546 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Edgewise Therapeutics, Inc. DEF 14A filed April 23, 2026, accession 0001104659-26-047688, and prior-year filings.
How this page was built: the Edgewise Therapeutics, Inc. filed document, accession 0001104659-26-047688. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 87,500 | $2,171,313 | — |
| RSU | 53,907 | $1,337,702 | — |
| Option | 91,667 | — | $10.39 |
| Option | 481,250 | — | $13.39 |
| Option | 287,500 | — | $17.05 |
| Option | 250,000 | — | $7.08 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Edgewise Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Edgewise Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kevin Koch · this page | President and Chief Executive Officer | $7,359,546 |
| Robert Blaustein | Former Chief Development Officer | $4,567,385 |
| Michael Nofi | Chief Financial Officer | $4,284,659 |
| Behrad Derakhshan | Chief Operating Officer | $2,933,228 |
| Joanne Donovan | Chief Medical Officer | $2,785,306 |
| Alan Russell | Co-Founder and Chief Scientific Officer | $2,734,849 |
| R. Michael Carruthers | Former Chief Financial Officer | $2,587,465 |
Board service
Edgewise Therapeutics board · FY2021–FY2025How this board is paid
Company policy: Edgewise Therapeutics pays directors a $40,000 cash retainer and $350,000 in Options. As stated in Edgewise Therapeutics's FY2025 proxy.
The full Edgewise Therapeutics compensation record
free company briefThis page is one person within Edgewise Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Edgewise Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Edgewise Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Edgewise Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.